# Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

> **NCT03550508** · PHASE1 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Bone Metastases

## Interventions

- **BIOLOGICAL:** Anti-RANKL Monoclonal Antibody

## Key facts

- **NCT ID:** NCT03550508
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-21
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-12-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03550508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03550508, "Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03550508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*